Birdwatch Note
2022-09-29 15:53:48 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Ivermectin has shown no benefit for the prevention or treatment of COVID-19 across multiple clinical trials: https://pubmed.ncbi.nlm.nih.gov/35726131/ https://pubmed.ncbi.nlm.nih.gov/35353979/ https://pubmed.ncbi.nlm.nih.gov/35179551/ https://pubmed.ncbi.nlm.nih.gov/35783616/ https://pubmed.ncbi.nlm.nih.gov/34483029/ The NIH's strongly recommends AGAINST the use of ivermectin for the treatment of COVID-19: https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/
Written by DA4507E4409ABAABB16D1F142ADEA36B
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1575160963321319424
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1575514186435764225
- noteId - 1575514186435764225
- participantId - DA4507E4409ABAABB16D1F142ADEA36B
- noteAuthorParticipantId -
- createdAtMillis - 1664466828341
- tweetId - 1575160963321319424
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable - BELIEVABLE_BY_MANY
- harmful - CONSIDERABLE_HARM
- validationDifficulty - CHALLENGING
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Ivermectin has shown no benefit for the prevention or treatment of COVID-19 across multiple clinical trials: https://pubmed.ncbi.nlm.nih.gov/35726131/ https://pubmed.ncbi.nlm.nih.gov/35353979/ https://pubmed.ncbi.nlm.nih.gov/35179551/ https://pubmed.ncbi.nlm.nih.gov/35783616/ https://pubmed.ncbi.nlm.nih.gov/34483029/ The NIH's strongly recommends AGAINST the use of ivermectin for the treatment of COVID-19: https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2022-09-29 15:53:48 UTC (1664466828341) |
2022-10-02 01:41:32 UTC (1664674892684) |
CURRENTLY_RATED_HELPFUL | 2022-10-02 01:41:32 UTC (1664674892684) |
NEEDS_MORE_RATINGS | 2022-10-02 01:41:32 UTC (1664674892684) |
CURRENTLY_RATED_HELPFUL | DA4507E4409ABAABB16D1F142ADEA36B |
| 2022-09-29 15:53:48 UTC (1664466828341) |
2022-10-02 01:41:32 UTC (1664674892684) |
CURRENTLY_RATED_HELPFUL | 2022-10-02 01:41:32 UTC (1664674892684) |
NEEDS_MORE_RATINGS | 2022-10-02 01:41:32 UTC (1664674892684) |
CURRENTLY_RATED_HELPFUL | 0B683F53A71314B5B037053E967D8B7476EE62CEC7C245474E462A3294BE2995 |
Note Ratings
| rated at | rated by | |
| 2022-09-29 22:10:19 -0500 | 04382F88D7BB0868181D119A55C579AD443BC0449C09870D3CCECB739859D397 | Rating Details |
| 2022-09-29 16:04:54 -0500 | 05412E105BB12814DCCCD4852D32177C | Rating Details |
| 2022-09-30 21:58:41 -0500 | 0F7322F328D9DD60F7C8EC0BDAD827F2877534D5DBCE183E0303BA1ADAC84AD5 | Rating Details |
| 2022-10-01 03:58:15 -0500 | 16D7355119A91A28351A822B5DD91AAF | Rating Details |
| 2022-09-30 22:15:00 -0500 | 1BCF64956E172871A5F5AA83B0081EDD1B7AAD17644913DF75C9B24003FBF60D | Rating Details |
| 2022-09-29 16:04:54 -0500 | 1C270D739DD955F219191BEECC4B956AE1C34532C74D4336129C5F8B56393BB4 | Rating Details |
| 2022-10-03 13:37:18 -0500 | 227B72516F48209D4CD398BD566B39A53B64980200BCA4A4C749072F49AA8384 | Rating Details |
| 2022-09-29 15:34:25 -0500 | 25B4E94C643BDEA7BE5BD8C068FCD16EE8B6962D3F2F75BE47131095A3017CA1 | Rating Details |
| 2022-09-30 12:36:53 -0500 | 2B4F4E1976DC66785DE41A759721DF86 | Rating Details |
| 2022-09-29 15:34:25 -0500 | 2C865626795ED6B6218C890EA61E723B | Rating Details |
| 2022-10-04 17:08:29 -0500 | 2C94EB9B3E60069AACE21497BAFCD58F | Rating Details |
| 2022-10-04 17:12:28 -0500 | 3616DD6CF3AA73638E881B3D762BB9CBE967778FDBD77798D64F131ECF5DB152 | Rating Details |
| 2022-09-29 11:00:07 -0500 | 38D6E46624CE956827B6CDF21C7E56B075BC3BE4883B190B6FB7F2E429B435F9 | Rating Details |
| 2022-09-29 11:26:37 -0500 | 39B450F35C1308A20A6AFA89A80AB520 | Rating Details |
| 2022-09-30 02:01:44 -0500 | 3E36586087A5AADDDB09CC96EF353B66AF3B7A0A6ACD36BBE6823ED342D938CC | Rating Details |
| 2022-10-19 21:45:00 -0500 | 460042217BE6C28B026CDDAA1805CBBB9A820B87C1CB9F96F9CC886D0B66C7AB | Rating Details |
| 2022-09-29 11:46:44 -0500 | 47AD3BD4ED0E64C9EA74DB3A322FA6AA5E5F8D84E57A6E405CC624F53C571EC8 | Rating Details |
| 2022-10-01 16:50:55 -0500 | 491F86E495D57AD373CE546FA4D9E4C79AB3B56F4BD9907D2CD96BB4578540B1 | Rating Details |
| 2022-10-04 17:12:28 -0500 | 4A879E63B3BDB1E8FA5478BE2B5306BD | Rating Details |
| 2022-10-06 14:09:13 -0500 | 4C469764969DECB6B384615994F8D98CC5397EF72995AC0CF933A9E7C502C2E1 | Rating Details |
| 2022-09-30 19:00:54 -0500 | 4C488781E0A43D6D28003A7D16CA021E6A3BEBD8AACDFC29F6B1CA45A8E6BCE7 | Rating Details |
| 2022-10-04 17:23:41 -0500 | 4F52DABE897BA667506ECCF2ADCF1E807150269909A26F405EE5D3E8E36DF2B7 | Rating Details |
| 2022-10-03 13:26:03 -0500 | 53C1765ABC48486852D4F9EF5991D556 | Rating Details |
| 2022-09-29 17:22:59 -0500 | 5763BF42FC42EAC8B8B6DD9F60F9F3F2BA0E67F9E3B7625849BAAF4382B52C7D | Rating Details |
| 2022-09-29 22:21:52 -0500 | 5808F68AADDE39547C80011478562A37F4DB3A90F72F9E6864404FF9AB7BF98D | Rating Details |
| 2022-09-30 15:46:18 -0500 | 5C46F05F831E79244F60645F43144FBFC3B470DAC34966F9851063B1332734A8 | Rating Details |
| 2022-09-30 22:15:00 -0500 | 5D70664F2FB225F5C656B03C81716986 | Rating Details |
| 2022-09-30 12:00:08 -0500 | 5F21704FA012DEA3240C4B02C5B0180D | Rating Details |
| 2022-10-03 21:02:14 -0500 | 6280708E53E8AA5916EABB58FB73A7C91C4FB392DFCC2C00D81618CC359E77F0 | Rating Details |
| 2022-09-30 12:17:35 -0500 | 6C4D39819380C974F26A34B6C85405BD | Rating Details |
| 2022-09-29 11:00:07 -0500 | 72248155A864C4A33B20212DF07B9A43 | Rating Details |
| 2022-09-29 16:57:54 -0500 | 7502FB4B7090A944287932A1B8348284 | Rating Details |
| 2022-09-30 12:36:53 -0500 | 770B9BBA1EAE656189E9D330BD064E4B32C5232762FF33E0EE06D148430F9CC1 | Rating Details |
| 2022-09-29 22:21:52 -0500 | 77909C3FD8470B33FBB3C70FFA3EC11F | Rating Details |
| 2022-10-01 00:13:50 -0500 | 78B9C824C57C685A61F13A37D207FEFB5B8C026B37764E7663FE06EE42FA090E | Rating Details |
| 2022-09-30 20:42:38 -0500 | 79A4EB5E995260044AC6A13EBA01ADCF | Rating Details |
| 2022-09-30 19:00:54 -0500 | 79D2BE8CA7F9CB473AB69B22745954B2 | Rating Details |
| 2022-10-04 17:23:41 -0500 | 7A68D08B67164A084E1E9CA22F0553C5 | Rating Details |
| 2022-10-04 17:14:44 -0500 | 922D1B20311E3B5E201AA75DBD757A2B42030A1DE15A83CBCEADD9A71A9080D7 | Rating Details |
| 2022-09-29 17:22:59 -0500 | 9466B3AC539AF0E5099B5FA99E829C3A | Rating Details |
| 2022-09-30 20:45:30 -0500 | 94CD19EF292A26A153CAE826E4CDC6F4759B42753EA2382090D83DEDB5223AF1 | Rating Details |
| 2022-09-29 11:46:44 -0500 | 9795BF8962792425EFA8D2F4F92685B4 | Rating Details |
| 2022-09-29 11:26:37 -0500 | 9A09F79F7A730ADB063362DEBEB03ABCC07142E2454E893E135AEA772204797E | Rating Details |
| 2022-09-30 12:00:08 -0500 | 9C1A980332A30BD29E2A58CC3492652436CDCEDF27639505968AF84E57A500F7 | Rating Details |
| 2022-09-30 12:17:35 -0500 | 9FDF9893DFAB4D45202E6558FAE3342DA24DFA5D58A9F7C14A2CF2DD79A3E176 | Rating Details |
| 2022-10-03 18:05:09 -0500 | AA0A0F1D04C40F36EACEF867E3B86522 | Rating Details |
| 2022-10-01 00:13:50 -0500 | AAA712DCF90BF3400651A10E6C1287D4 | Rating Details |
| 2022-09-30 20:45:30 -0500 | ADA9C07D1B0CB80F9645D77C2465C880 | Rating Details |
| 2022-10-03 13:37:18 -0500 | B47391ADD314142E98ADB1447C70FB98 | Rating Details |
| 2022-10-04 17:09:17 -0500 | B7DAE6848130396185F4D0CCE1630CC47956F44A68389D3D2279E1BA337FB421 | Rating Details |
| 2022-10-04 17:08:29 -0500 | BF227F61A7D83DA7D71295779FE6EA1EAEC1BC39EA7A2626BE31E89DF540D546 | Rating Details |
| 2022-10-01 03:58:15 -0500 | CBF40D19855B098E8891A91C023695C1DDAE26A463C2BA9F00A792C9E90FF264 | Rating Details |
| 2022-09-30 15:46:18 -0500 | CD856CADFA8F635D3E24419651F09931 | Rating Details |
| 2022-10-01 16:50:55 -0500 | CD9D49DCCCDDE369B34482B66E49E224 | Rating Details |
| 2022-10-03 13:26:03 -0500 | E87EE2844723AF6921C9CB9520F13968D825D7359E96FB395389414B7368A681 | Rating Details |
| 2022-09-29 16:57:54 -0500 | ED81A6F8124E2C0B1426A10C31D5628817026FB28BC3D75FD48443D0F76AF0A5 | Rating Details |
| 2022-10-03 18:05:09 -0500 | F18364DEDA06CAFD84D0C83E525159118BF1F863FF927B9421C3F7EC6C975B8E | Rating Details |
| 2022-09-30 20:42:38 -0500 | FCE7F035C82EEE4DC4745E5A85B40BCA27FA681B6028E21EF7B68EB36AA75DC3 | Rating Details |
| 2023-04-03 14:08:34 -0500 | Rating Details | |
| 2022-10-11 21:58:20 -0500 | Rating Details | |
| 2022-10-03 15:00:47 -0500 | Rating Details | |
| 2022-10-04 17:26:51 -0500 | Rating Details | |
| 2022-09-29 21:22:48 -0500 | Rating Details | |
| 2022-10-06 23:26:50 -0500 | Rating Details | |
| 2022-10-09 13:46:53 -0500 | Rating Details | |
| 2022-10-05 09:50:20 -0500 | Rating Details | |
| 2022-10-04 20:33:17 -0500 | Rating Details | |
| 2022-10-05 10:59:28 -0500 | Rating Details | |
| 2022-09-29 16:04:54 -0500 | Rating Details | |
| 2022-10-04 17:09:17 -0500 | Rating Details | |
| 2022-10-04 17:23:41 -0500 | Rating Details | |
| 2022-10-06 14:09:13 -0500 | Rating Details | |
| 2022-10-04 17:08:29 -0500 | Rating Details | |
| 2022-09-30 20:42:38 -0500 | Rating Details | |
| 2022-10-01 03:58:15 -0500 | Rating Details | |
| 2022-10-11 21:58:20 -0500 | Rating Details | |
| 2022-09-30 22:15:00 -0500 | Rating Details | |
| 2022-10-04 17:12:28 -0500 | Rating Details | |
| 2022-10-03 15:00:47 -0500 | Rating Details | |
| 2022-10-01 00:13:50 -0500 | Rating Details | |
| 2022-09-29 22:21:52 -0500 | Rating Details | |
| 2022-10-04 17:14:44 -0500 | Rating Details | |
| 2022-10-04 17:26:51 -0500 | Rating Details | |
| 2022-09-30 20:45:30 -0500 | Rating Details | |
| 2022-09-29 15:34:25 -0500 | Rating Details | |
| 2022-09-30 21:58:41 -0500 | Rating Details | |
| 2022-10-03 21:02:14 -0500 | Rating Details | |
| 2022-10-01 16:50:55 -0500 | Rating Details | |
| 2022-09-29 21:22:48 -0500 | Rating Details | |
| 2023-04-03 14:08:34 -0500 | Rating Details | |
| 2022-09-29 17:22:59 -0500 | Rating Details | |
| 2022-10-06 23:26:50 -0500 | Rating Details | |
| 2022-10-19 21:45:00 -0500 | Rating Details | |
| 2022-10-09 13:46:53 -0500 | Rating Details | |
| 2022-09-29 11:00:07 -0500 | Rating Details | |
| 2022-09-30 12:17:35 -0500 | Rating Details | |
| 2022-09-30 15:46:18 -0500 | Rating Details | |
| 2022-09-29 22:10:19 -0500 | Rating Details | |
| 2022-09-30 02:01:44 -0500 | Rating Details | |
| 2022-09-30 19:00:54 -0500 | Rating Details | |
| 2022-10-03 13:26:03 -0500 | Rating Details | |
| 2022-09-30 12:00:08 -0500 | Rating Details | |
| 2022-10-03 13:37:18 -0500 | Rating Details | |
| 2022-09-30 12:36:53 -0500 | Rating Details | |
| 2022-09-29 16:57:54 -0500 | Rating Details | |
| 2022-09-29 11:46:44 -0500 | Rating Details | |
| 2022-10-05 09:50:20 -0500 | Rating Details | |
| 2022-10-03 18:05:09 -0500 | Rating Details | |
| 2022-10-04 20:33:17 -0500 | Rating Details | |
| 2022-10-05 10:59:28 -0500 | Rating Details |